This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \& CD22 bispecific CAR-T cells in relapsed / refractory B cell hematological tumors while collecting pharmacokinetics and pharmacodynamics indicators of CAR-T cells.
HGB≥70g/L(transfusible)
Liver and kidney function: creatinine ≤1.5XULN: total bilirubin ≤1.5XULN:ALT and AST≤2.5X ULN
Cardiopulmonary function: left ventricular ejection fraction >50%; Blood oxygen saturation >90%;
Serious heart insufficiency,LVEF <50%
History of severe pulmonary function impairment disease.
Other malignant tumors in the advanced stage.
Severe infection or persistent infection that cannot be effectively controlled.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead sponsor
Hebei Taihe Chunyu Biotechnology Co., Ltd
Collaborator